Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Cervical Cancer

Free Subscription Articles published in Gynecol Oncol Retrieve available abstracts of 237 articles: HTML format

Single Articles

April 2024
1. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
   Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
   Gynecol Oncol. 2024;186:35-41.
   PubMed     Abstract available
   
   
   March 2024
2. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
   Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
   Gynecol Oncol. 2024;183:33-38.
   PubMed     Abstract available
   
   
   
3. GASS P, Thiel FC, Haberle L, Ackermann S, et al
   Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
   Gynecol Oncol. 2024;183:25-32.
   PubMed     Abstract available
   
   
   February 2024
4. ROOF KA, Wichmann HK, Carlton LJ, Nguyen ML, et al
   Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy.
   Gynecol Oncol. 2024;185:46-50.
   PubMed     Abstract available
   
   
   
5. KUCERA CW, Chappell NP, Tian C, Richardson MT, et al
   Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors.
   Gynecol Oncol. 2024;184:224-235.
   PubMed     Abstract available
   
   
   
6. DINICU AI, Dioun S, Wang Y, Huang Y, et al
   Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care.
   Gynecol Oncol. 2024;184:214-223.
   PubMed     Abstract available
   
   
   
7. PELTECU G
   Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
   Gynecol Oncol. 2024;181:40-45.
   PubMed     Abstract available
   
   
   January 2024
8. DORISMOND VG, Saraiya M, Gopalani SV, Soman A, et al
   Variation in cervical cancer screening test utilization and results in a United States-based program.
   Gynecol Oncol. 2024;184:96-102.
   PubMed     Abstract available
   
   
   
9. BEFANO B, Wentzensen N, Lorey T, Poitras N, et al
   Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
   Gynecol Oncol. 2024;184:89-95.
   PubMed     Abstract available
   
   
   
10. MANNING-GEIST B, Grace MA, Sonoda Y
    Trachelectomy and fertility-sparing procedures for early-stage cervical cancer: A state of the science review.
    Gynecol Oncol. 2024;181:179-182.
    PubMed    
    
    
    
11. LEE SS, Gold HT, Kwon SC, Pothuri B, et al
    Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis.
    Gynecol Oncol. 2024;182:132-140.
    PubMed     Abstract available
    
    
    
12. CHOI KH, Lee HC, Kim YS, Park W, et al
    Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study.
    Gynecol Oncol. 2024;182:45-50.
    PubMed     Abstract available
    
    
    
13. FRIEDMAN CF, D'Souza A, Bello Roufai D, Tinker AV, et al
    Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Gynecol Oncol. 2024;181:162-169.
    PubMed     Abstract available
    
    
    December 2023
14. TJIOE KC, Miranda-Galvis M, Johnson MS, Agrawal G, et al
    The interaction between social determinants of health and cervical cancer survival: A systematic review.
    Gynecol Oncol. 2023;181:141-154.
    PubMed     Abstract available
    
    
    
15. HALLE MK, Bozickovic O, Forsse D, Wagner-Larsen KS, et al
    Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer.
    Gynecol Oncol. 2023;181:110-117.
    PubMed     Abstract available
    
    
    
16. RIVES TA, Orellana TJ, Mumford BS, Sukumvanich P, et al
    The role of obesity in treatment planning for early-stage cervical cancer.
    Gynecol Oncol. 2023;181:60-67.
    PubMed     Abstract available
    
    
    
17. URBUTE A, Frederiksen K, Thomsen LT, Kesmodel US, et al
    Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study.
    Gynecol Oncol. 2023;181:20-27.
    PubMed     Abstract available
    
    
    
18. VAHTERISTO M, Leinonen MK, Sarkeala T, Anttila A, et al
    Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
    Gynecol Oncol. 2023;180:146-151.
    PubMed     Abstract available
    
    
    
19. HSIEH K, Bloom JR, Dickstein DR, Hsieh C, et al
    Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
    Gynecol Oncol. 2023;180:55-62.
    PubMed     Abstract available
    
    
    
20. RAI R, Lightfoot S, Benbrook DM
    Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts.
    Gynecol Oncol. 2023;180:44-54.
    PubMed     Abstract available
    
    
    
21. SAMMOURI J, Venkatesan AM, Lin LL, Jhingran A, et al
    Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement.
    Gynecol Oncol. 2023;180:24-34.
    PubMed     Abstract available
    
    
    
22. LONG E, Macdonald MC, Parker VL, Lyon R, et al
    Factors associated with failed 'test of cure' in the NHS Cervical Screening Programme: A retrospective cohort study.
    Gynecol Oncol. 2023;179:158-163.
    PubMed     Abstract available
    
    
    November 2023
23. NASIOUDIS D, Gysler S, Latif N, Cory L, et al
    Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Gynecol Oncol. 2023;180:1-5.
    PubMed     Abstract available
    
    
    
24. HERMANN CE, Patel JM, Boyd L, Growdon WB, et al
    Let's chat about cervical cancer: Assessing the accuracy of ChatGPT responses to cervical cancer questions.
    Gynecol Oncol. 2023;179:164-168.
    PubMed     Abstract available
    
    
    
25. GIRDA E, Randall LM, Chino F, Monk BJ, et al
    Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2023;179:115-122.
    PubMed     Abstract available
    
    
    
26. KUMAR R, Sherwani Z, Lopez M, Vergalasova I, et al
    Disparities in brachytherapy utilization in cervical cancer in the United States: A comprehensive literature review.
    Gynecol Oncol. 2023;179:79-84.
    PubMed     Abstract available
    
    
    
27. WICKENHEISSER NE, Dillon M, Broadwater G, Zacherl K, et al
    Radical hysterectomy case volume and cervical cancer treatment in the era of COVID-19: A multi-site analysis of National Cancer Institute-designated Comprehensive Cancer Centers.
    Gynecol Oncol. 2023;179:70-78.
    PubMed     Abstract available
    
    
    
28. SUMMEY R, Benoit M, Williams-Brown MY
    Survival differences by race and surgical approach in early-stage operable cervical Cancer.
    Gynecol Oncol. 2023;179:63-69.
    PubMed     Abstract available
    
    
    
29. CHEN F, Zhang GN, Lei W, Zhou SG, et al
    Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
    Gynecol Oncol. 2023;178:8-13.
    PubMed     Abstract available
    
    
    October 2023
30. BAETEN IGT, Hoogendam JP, Schreuder HWR, Jurgenliemk-Schulz IM, et al
    Introducing a novice surgeon to an experienced robotic gynaecological oncology team: An observational cohort study on the impact of a structured curriculum on outcomes of cervical cancer surgery.
    Gynecol Oncol. 2023;178:153-160.
    PubMed     Abstract available
    
    
    
31. CHAPMAN GC, Smrz SA, Gordon JC, Lynam SK, et al
    Gynecologic cancer care in the first year of the COVID-19 pandemic.
    Gynecol Oncol. 2023;178:138-144.
    PubMed     Abstract available
    
    
    September 2023
32. AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
    Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:157-164.
    PubMed     Abstract available
    
    
    
33. LEE HC, Jeong JW, Lee JH, Kim SH, et al
    High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
    Gynecol Oncol. 2023;177:142-149.
    PubMed     Abstract available
    
    
    
34. PRAISS AM, Allison D, Tessier-Cloutier B, Flynn J, et al
    Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study.
    Gynecol Oncol. 2023;176:147-154.
    PubMed     Abstract available
    
    
    August 2023
35. KOROMPELIS P, Rundle S, Cassar V, Ratnavelu N, et al
    "Conservative surgical approaches for small volume FIGO stage IB1 cervical cancer. Updated survival and obstetric outcomes of an expanded cohort".
    Gynecol Oncol. 2023;176:155-161.
    PubMed     Abstract available
    
    
    July 2023
36. KONG TW, Kim J, Son JH, Lee AJ, et al
    Is minimally invasive radical surgery safe for patients with cervical cancer
    Gynecol Oncol. 2023;176:122-129.
    PubMed     Abstract available
    
    
    
37. EIDE AJ, Halle MK, Lura N, Fasmer KE, et al
    Visceral fat percentage for prediction of outcome in uterine cervical cancer.
    Gynecol Oncol. 2023;176:62-68.
    PubMed     Abstract available
    
    
    
38. KAHVECIOGLU A, Gurlek E, Yedekci FY, Sari SY, et al
    Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2023;176:10-15.
    PubMed     Abstract available
    
    
    June 2023
39. KONSKI A, Deshmukh S, Klopp AH, Yeung AR, et al
    Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.
    Gynecol Oncol. 2023;175:176-181.
    PubMed     Abstract available
    
    
    
40. MAH SJ, Carter Ramirez DM, Eiriksson LR, Schnarr K, et al
    Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018.
    Gynecol Oncol. 2023;175:169-175.
    PubMed     Abstract available
    
    
    
41. LI J, Xue X, Zhang Y, Ding F, et al
    The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
    Gynecol Oncol. 2023;175:133-141.
    PubMed     Abstract available
    
    
    
42. MORTON M, Haight PJ, Khadraoui W, Backes F, et al
    "More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
    Gynecol Oncol. 2023;175:81-87.
    PubMed     Abstract available
    
    
    
43. KULKARNI A, Chen L, Gockley A, Khoury-Collado F, et al
    Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Gynecol Oncol. 2023;175:53-59.
    PubMed     Abstract available
    
    
    
44. LEVINE MD, Barrington DA, Meade CE, Lammers SM, et al
    Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
    Gynecol Oncol. 2023;173:15-21.
    PubMed     Abstract available
    
    
    May 2023
45. SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
    The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
    Gynecol Oncol. 2023;174:253-261.
    PubMed     Abstract available
    
    
    
46. KIM NR, Kim SI, Suh DH, Kim HS, et al
    Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors.
    Gynecol Oncol. 2023;174:224-230.
    PubMed     Abstract available
    
    
    
47. HAN L, Chen Y, Zheng A, Chen H, et al
    Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;174:167-174.
    PubMed     Abstract available
    
    
    
48. VERGOTE I, Van Nieuwenhuysen E, Casado A, Laenen A, et al
    Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
    Gynecol Oncol. 2023;174:80-88.
    PubMed     Abstract available
    
    
    
49. ROBOVA H, Rob L, Halaska MJ, Drozenova J, et al
    Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Pregnancy outcomes.
    Gynecol Oncol. 2023;174:76-79.
    PubMed     Abstract available
    
    
    
50. DI DONATO V, Bogani G, Casarin J, Ghezzi F, et al
    Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for "low-risk" early-stage cervical cancer: A propensity-score based analysis.
    Gynecol Oncol. 2023;174:49-54.
    PubMed     Abstract available
    
    
    
51. STOLER MH, Parvu V, Yanson K, Andrews J, et al
    Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2023;174:68-75.
    PubMed     Abstract available
    
    
    
52. PIEDIMONTE S, Helpman L, Pond G, Nelson G, et al
    Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study.
    Gynecol Oncol. 2023;174:21-27.
    PubMed     Abstract available
    
    
    
53. FUREY KB, Anderson ZS, Kuznicki ML, Klar M, et al
    Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer.
    Gynecol Oncol. 2023;173:122-129.
    PubMed     Abstract available
    
    
    April 2023
54. KIM SI, Nam SH, Hwangbo S, Kim Y, et al
    Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R).
    Gynecol Oncol. 2023;173:88-97.
    PubMed     Abstract available
    
    
    
55. GARCIA-SAYRE J, Lin YG, Matuso K, Tsao-Wei DD, et al
    Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
    Gynecol Oncol. 2023;173:49-57.
    PubMed     Abstract available
    
    
    
56. CIBULA D
    The group with the most heterogenous treatment among patients with cervical cancer.
    Gynecol Oncol. 2023 Apr 17:S0090-8258(23)00169.
    PubMed    
    
    
    March 2023
57. TEWARI KS, Sill MW, Birrer MJ, Penson RT, et al
    Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study.
    Gynecol Oncol. 2023;171:141-150.
    PubMed     Abstract available
    
    
    
58. MOOLENAAR LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, et al
    Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Gynecol Oncol. 2023;171:114-120.
    PubMed     Abstract available
    
    
    
59. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    PubMed     Abstract available
    
    
    February 2023
60. BENBROOK DM, Deng W, Gold MA, Rai R, et al
    Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
    Gynecol Oncol. 2023;171:67-75.
    PubMed     Abstract available
    
    
    
61. VAN KOL KGG, Ebisch RMF, van der Aa M, Wenzel HB, et al
    The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
    Gynecol Oncol. 2023;171:9-14.
    PubMed     Abstract available
    
    
    
62. KIM C, Salvo G, Ishikawa M, Chen TC, et al
    The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis.
    Gynecol Oncol. 2023;170:328-332.
    PubMed     Abstract available
    
    
    
63. KISSEL M, Balaya V, Guani B, Magaud L, et al
    Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials.
    Gynecol Oncol. 2023;170:309-316.
    PubMed     Abstract available
    
    
    
64. KAUR A, Wang S, Kumar A
    Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
    Gynecol Oncol. 2023;170:266-272.
    PubMed     Abstract available
    
    
    
65. HOLLOWAY SB, Mercadel AJ, Miller DS, Lea JS, et al
    Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.
    Gynecol Oncol. 2023;170:248-253.
    PubMed     Abstract available
    
    
    
66. BOITANO TKL, Scarinci IC
    Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer.
    Gynecol Oncol. 2023;169:A1-A2.
    PubMed    
    
    
    January 2023
67. CIBULA D, Akilli H, Jarkovsky J, van Lonkhuijzen L, et al
    Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
    Gynecol Oncol. 2023;170:195-202.
    PubMed     Abstract available
    
    
    
68. SUVAAL I, Kirchheiner K, Nout RA, Sturdza AE, et al
    Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy.
    Gynecol Oncol. 2023;170:123-132.
    PubMed     Abstract available
    
    
    
69. SMITS A, Ten Eikelder M, Dhanis J, Moore W, et al
    Finding the sentinel lymph node in early cervical cancer: When is unusual not uncommon?
    Gynecol Oncol. 2023;170:84-92.
    PubMed     Abstract available
    
    
    
70. LU L, Liu T, Wang S, Li J, et al
    Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases.
    Gynecol Oncol. 2023;170:59-69.
    PubMed     Abstract available
    
    
    December 2022
71. CASTELLANO T, Moore K, Ting J, Washington C, et al
    Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2022;169:113-117.
    PubMed     Abstract available
    
    
    
72. LI X, Jiang Z, Lu J, Chen X, et al
    Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer.
    Gynecol Oncol. 2022;169:106-112.
    PubMed     Abstract available
    
    
    
73. LIN MY, Mileshkin L, McNally O, Kondalsamy-Chennakesavan S, et al
    Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection.
    Gynecol Oncol. 2022;169:91-97.
    PubMed     Abstract available
    
    
    
74. EHMANN S, Sassine D, Straubhar AM, Praiss AM, et al
    Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
    Gynecol Oncol. 2022;167:458-466.
    PubMed     Abstract available
    
    
    November 2022
75. VIEIRA-SERNA S, Viveros-Carreno D, Rodriguez J, Grillo-Ardila CF, et al
    Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022;169:4-11.
    PubMed     Abstract available
    
    
    
76. DOSTALEK L, Benesova K, Klat J, Kim SH, et al
    Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
    Gynecol Oncol. 2022;168:151-156.
    PubMed     Abstract available
    
    
    
77. BRUEGL AS, Emerson J, Tirumala K
    Persistent disparities of cervical cancer among American Indians/Alaska natives: Are we maximizing prevention tools?
    Gynecol Oncol. 2022;168:56-61.
    PubMed     Abstract available
    
    
    
78. KNAUSS T, Hansen BT, Pedersen K, Aasbo G, et al
    The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
    Gynecol Oncol. 2022;168:39-47.
    PubMed     Abstract available
    
    
    
79. KA K, Laville A, Rassy E, Ayachi RE, et al
    Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
    Gynecol Oncol. 2022;168:32-38.
    PubMed     Abstract available
    
    
    October 2022
80. PERKINS R, Jeronimo J, Hammer A, Novetsky A, et al
    Comparison of accuracy and reproducibility of colposcopic impression based on a single image versus a two-minute time series of colposcopic images.
    Gynecol Oncol. 2022;167:89-95.
    PubMed     Abstract available
    
    
    
81. CHEN H, Xiong W, Dong X, Liu Y, et al
    Infection status and survival impact of high-risk human papillomavirus in cervical adenocarcinomas: A systematic review and meta-analysis.
    Gynecol Oncol. 2022;167:129-136.
    PubMed     Abstract available
    
    
    September 2022
82. HOLM J, Gerke O, Vilstrup MH, Spasojevic D, et al
    Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
    Gynecol Oncol. 2022 Sep 28. pii: S0090-8258(22)01841.
    PubMed     Abstract available
    
    
    
83. RONSINI C, Kohler C, de Franciscis P, La Verde M, et al
    Laparo-assisted vaginal radical hysterectomy as a safe option for minimal invasive surgery in early stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)00580.
    PubMed     Abstract available
    
    
    
84. LEE YW, Morgan JR, Fiascone S, Perkins RB, et al
    Underscreenng, overscreening, and guideline-adherent cervical cancer screening in a national cohort.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01826.
    PubMed     Abstract available
    
    
    
85. PUJADE-LAURAINE E, Tan DSP, Leary A, Mirza MR, et al
    Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00552.
    PubMed     Abstract available
    
    
    August 2022
86. KIM Y, Kim SI, Kim H, Lee M, et al
    Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00541.
    PubMed     Abstract available
    
    
    
87. VAHTERISTO M, Heinavaara S, Anttila A, Sarkeala T, et al
    Alternative cytology triage strategies for primary HPV screening.
    Gynecol Oncol. 2022 Aug 10. pii: S0090-8258(22)00495.
    PubMed     Abstract available
    
    
    July 2022
88. SIVARS L, Hellman K, Crona Guterstam Y, Holzhauser S, et al
    Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00512.
    PubMed     Abstract available
    
    
    
89. ALHOLM Z, He D, Ting J, Zhang YJ, et al
    Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
    Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00509.
    PubMed     Abstract available
    
    
    
90. BOGANI G, Donato VD, Scambia G, Landoni F, et al
    Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer.
    Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00494.
    PubMed     Abstract available
    
    
    
91. LEITAO MM JR, Zhou QC, Brandt B, Iasonos A, et al
    The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00434.
    PubMed     Abstract available
    
    
    
92. LI H, Wang S, Liu Y, Wang T, et al
    Prophylactic extended-field irradiation for locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jul 19. pii: S0090-8258(22)00481.
    PubMed     Abstract available
    
    
    
93. CHERSTON C, Yoh K, Huang Y, Melamed A, et al
    Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
    Gynecol Oncol. 2022 Jul 1. pii: S0090-8258(22)00427.
    PubMed     Abstract available
    
    
    June 2022
94. SY F, Greuel M, Winkler V, Bussmann H, et al
    Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00416.
    PubMed     Abstract available
    
    
    
95. ROGOWSKI P, Rottler M, Walter F, Saicic S, et al
    Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
    Gynecol Oncol. 2022 Jun 25. pii: S0090-8258(22)00423.
    PubMed     Abstract available
    
    
    
96. BACORRO W, Baldivia K, Yu KK, Mariano J, et al
    Outcomes with definitive radiotherapy among patients with locally advanced cervical cancer with relative or absolute contraindications to cisplatin: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jun 24. pii: S0090-8258(22)00422.
    PubMed     Abstract available
    
    
    
97. RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
    Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00418.
    PubMed     Abstract available
    
    
    
98. SCHIFF JP, Mintz R, Cohen AC, Huang Y, et al
    Overall survival in patients with FIGO stage IVA cervical cancer.
    Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00333.
    PubMed     Abstract available
    
    
    
99. ZHOU N, Cui Y, Zhu R, Kuang Y, et al
    Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00306.
    PubMed     Abstract available
    
    
    
100. HORSBOL TA, Kjaer SK, Andersen EW, Ammitzboll G, et al
     Use of hypnotics among women diagnosed with cervical cancer - A population-based cohort study.
     Gynecol Oncol. 2022 Jun 6. pii: S0090-8258(22)00330.
     PubMed     Abstract available
     
     
     
101. MARTIN AL, Sinha S, Peres LC, Hakam A, et al
     The impact of distance to closest negative margin on survival after pelvic exenteration.
     Gynecol Oncol. 2022;165:514-521.
     PubMed     Abstract available
     
     
     May 2022
102. PIEDIMONTE S, Pond GR, Plante M, Nelson G, et al
     Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
     Gynecol Oncol. 2022 May 26. pii: S0090-8258(22)00310.
     PubMed     Abstract available
     
     
     
103. GENNARI P, Tchaikovski S, Meszaros J, Gerken M, et al
     Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.
     Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00313.
     PubMed     Abstract available
     
     
     
104. ZHOU S, Liu S, Tian G, Zhao L, et al
     KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer.
     Gynecol Oncol. 2022 May 17. pii: S0090-8258(22)00309.
     PubMed     Abstract available
     
     
     
105. MCKINNISH TR, Greenwade MM, Wilkinson-Ryan I, Schwarz JK, et al
     Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
     Gynecol Oncol. 2022 May 7. pii: S0090-8258(22)00259.
     PubMed     Abstract available
     
     
     
106. RONSINI C, Kohler C, De Franciscis P, La Verde M, et al
     Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis.
     Gynecol Oncol. 2022 May 2. pii: S0090-8258(22)00251.
     PubMed     Abstract available
     
     
     
107. KIM SK, Ursell P, Coleman RL, Monk BJ, et al
     Mitigation and management strategies for ocular events associated with tisotumab vedotin.
     Gynecol Oncol. 2022;165:385-392.
     PubMed     Abstract available
     
     
     April 2022
108. THOMAS RJ, Provenzano D, Goyal S, Loew M, et al
     Trends in guideline-adherent chemoradiation therapy for locally advanced cervical cancer before and after the affordable care act.
     Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00256.
     PubMed     Abstract available
     
     
     
109. JACKSON CG, Moore KN, Cantrell L, Erickson BK, et al
     A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
     Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00257.
     PubMed     Abstract available
     
     
     
110. XU JY, Chen JN, Lei J, Hu M, et al
     Local treatment improves survival in patients with stage IVB cervical cancer.
     Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00254.
     PubMed     Abstract available
     
     
     
111. TANIGAWA T, Takeshima N, Ishikawa H, Nishio S, et al
     Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
     Gynecol Oncol. 2022 Apr 26. pii: S0090-8258(22)00252.
     PubMed     Abstract available
     
     
     
112. POTHURI B, Eskander RN, Randall LM, O'Malley DM, et al
     Practice changing cervical cancer clinical trials.
     Gynecol Oncol. 2022 Apr 20. pii: S0090-8258(22)00175.
     PubMed    
     
     
     
113. LUHRS O, Bollino M, Ekdahl L, Lonnerfors C, et al
     Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy.
     Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00209.
     PubMed     Abstract available
     
     
     
114. BARRINGTON DA, Riedinger C, Haight PJ, Tubbs C, et al
     Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
     Gynecol Oncol. 2022 Apr 11. pii: S0090-8258(22)00213.
     PubMed     Abstract available
     
     
     
115. SAPIENZA LG, Thomas JJ, Showalter TN, Echeverria AE, et al
     Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.
     Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00208.
     PubMed     Abstract available
     
     
     
116. SAND FL, Frederiksen K, Kjaer SK
     Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins.
     Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00197.
     PubMed     Abstract available
     
     
     
117. SALVO G, Jhingran A, Ramalingam P, Legarreta AF, et al
     Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
     Gynecol Oncol. 2022 Apr 5. pii: S0090-8258(22)00204.
     PubMed     Abstract available
     
     
     
118. POLTERAUER S, Reich O, Widschwendter A, Hadjari L, et al
     Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.
     Gynecol Oncol. 2022;165:23-29.
     PubMed     Abstract available
     
     
     
119. LIAO X, Xia X, Su W, Yan H, et al
     Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
     Gynecol Oncol. 2022;165:105-113.
     PubMed     Abstract available
     
     
     
120. KASHOFER K, Regauer S, Reich O, Petru E, et al
     Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
     Gynecol Oncol. 2022;165:121-128.
     PubMed     Abstract available
     
     
     March 2022
121. MOHAMUD A, Hogdall C, Schnack T
     Prognostic value of the 2018 FIGO staging system for cervical cancer.
     Gynecol Oncol. 2022 Mar 25. pii: S0090-8258(22)00127.
     PubMed     Abstract available
     
     
     
122. HACK AP, Zweemer RP, Jonges TN, van der Leij F, et al
     Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study.
     Gynecol Oncol. 2022 Mar 14. pii: S0090-8258(22)00177.
     PubMed     Abstract available
     
     
     
123. LEITAO MM JR
     The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching.
     Gynecol Oncol. 2022;164:461-462.
     PubMed    
     
     
     February 2022
124. PH M, Maulard A, Scherier S, Sanson C, et al
     Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review.
     Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00051.
     PubMed     Abstract available
     
     
     
125. GOINS EC, Weber JM, Truong T, Moss HA, et al
     Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
     Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
     PubMed     Abstract available
     
     
     
126. KOBAYASHI E, Nakatani E, Tanaka T, Yosuke K, et al
     Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
     Gynecol Oncol. 2022 Feb 24. pii: S0090-8258(22)00089.
     PubMed     Abstract available
     
     
     
127. BAETEN IGT, Hoogendam JP, Jonges GN, Jurgenliemk-Schulz IM, et al
     Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer.
     Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00121.
     PubMed     Abstract available
     
     
     
128. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
     Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
     Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
     PubMed     Abstract available
     
     
     
129. YAHATA H, Kodama K, Okugawa K, Hachisuga K, et al
     Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer.
     Gynecol Oncol. 2022 Feb 9. pii: S0090-8258(22)00070.
     PubMed     Abstract available
     
     
     January 2022
130. LICHTER KE, Levinson K, Hammer A, Lippitt MH, et al
     Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
     Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00025.
     PubMed     Abstract available
     
     
     
131. YAN L, Liu Y, Zhang J, Chen X, et al
     In vivo and in vitro study of the potential hazards of surgical smoke during cervical cancer treatment with an ultrasonic scalpel.
     Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00008.
     PubMed     Abstract available
     
     
     
132. MUSA FB, Brouwer E, Ting J, Schwartz NRM, et al
     Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
     Gynecol Oncol. 2022 Jan 11. pii: S0090-8258(21)01696.
     PubMed     Abstract available
     
     
     
133. AMPOFO AG, Boyes AW, Khumalo PG, Mackenzie L, et al
     Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education.
     Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01680.
     PubMed     Abstract available
     
     
     
134. WANG J, Dong J, Zhou Y, Wang K, et al
     Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
     Gynecol Oncol. 2022 Jan 4. pii: S0090-8258(21)01701.
     PubMed     Abstract available
     
     
     
135. BORCINOVA M, Ragosch V, Jarkovsky J, Bajsova S, et al
     Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study.
     Gynecol Oncol. 2022;164:76-84.
     PubMed     Abstract available
     
     
     December 2021
136. EKDAHL L, Paraghamian S, Eoh KJ, Thumuluru KM, et al
     Long term oncologic and reproductive outcomes after robot-assisted radical trachelectomy for early-stage cervical cancer. An international multicenter study.
     Gynecol Oncol. 2021 Dec 31. pii: S0090-8258(21)01697.
     PubMed     Abstract available
     
     
     
137. CORRIGAN KL, Yoder A, De B, Lin L, et al
     Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
     Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
     PubMed     Abstract available
     
     
     
138. SPONHOLTZ SE, Ezendam NPM, de Rooij BH, Parner E, et al
     SENTIREC - The sentinel node mapping in women with cervical cancer study - Patient-reported early lymphedema and its impact on quality of life.
     Gynecol Oncol. 2021 Dec 29. pii: S0090-8258(21)01692.
     PubMed     Abstract available
     
     
     
139. KIM SI, Choi BR, Kim HS, Chung HH, et al
     Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach.
     Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01691.
     PubMed     Abstract available
     
     
     
140. THELISSEN AAB, Jurgenliemk-Schulz IM, van der Leij F, Peters M, et al
     Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis.
     Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01694.
     PubMed     Abstract available
     
     
     
141. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
     Post-recurrence survival in patients with cervical cancer.
     Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01675.
     PubMed     Abstract available
     
     
     
142. GUANI B, Mahiou K, Crestani A, Cibula D, et al
     Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis.
     Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01672.
     PubMed     Abstract available
     
     
     
143. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
     Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
     Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
     PubMed     Abstract available
     
     
     
144. SHI Y, Chen J, Shi B, Liu A, et al
     Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
     Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01633.
     PubMed     Abstract available
     
     
     
145. SWIFT BE, Maeda A, Bouchard-Fortier G
     Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
     Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
     PubMed     Abstract available
     
     
     
146. DEBOER RJ, Umutoni V, Bazzett-Matabele L, Katznelson E, et al
     Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
     Gynecol Oncol. 2021 Dec 13. pii: S0090-8258(21)01628.
     PubMed     Abstract available
     
     
     
147. KORENAGA TK, Yoshida EJ, Pierson W, Chang J, et al
     Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
     Gynecol Oncol. 2021 Dec 2. pii: S0090-8258(21)01608.
     PubMed     Abstract available
     
     
     November 2021
148. MANZOUR N, Nunez-Cordoba JM, Chiva L, Chacon E, et al
     Pattern of relapse in patients with stage IB1 cervical cancer after radical hysterectomy as primary treatment. Minimally invasive surgery vs. open approach. Systematic review and meta-analysis.
     Gynecol Oncol. 2021 Nov 27. pii: S0090-8258(21)01623.
     PubMed     Abstract available
     
     
     
149. ARYASOMAYAJULA C, Chanana A, Tandel M, Kwan L, et al
     The role of high-risk HPV testing in cervical cancer surveillance.
     Gynecol Oncol. 2021 Nov 23. pii: S0090-8258(21)01606.
     PubMed     Abstract available
     
     
     
150. HUANG J, Deng Y, Boakye D, Tin MS, et al
     Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis.
     Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01598.
     PubMed     Abstract available
     
     
     
151. MENG Y, Chu T, Lin S, Wu P, et al
     Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
     Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01451.
     PubMed     Abstract available
     
     
     October 2021
152. CHARGARI C, Arbyn M, Leary A, Abu-Rustum NR, et al
     Increasing global accessibility to high-level treatments for cervical cancers.
     Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01517.
     PubMed     Abstract available
     
     
     
153. BALAYA V, Guani B, Morice P, Querleu D, et al
     Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.
     Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01518.
     PubMed     Abstract available
     
     
     
154. SHIN W, Park SY, Seo SS, Lim MC, et al
     Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.
     Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01514.
     PubMed     Abstract available
     
     
     
155. HE WQ, Li C
     Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends.
     Gynecol Oncol. 2021 Oct 20. pii: S0090-8258(21)01519.
     PubMed     Abstract available
     
     
     
156. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
     Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].
     Gynecol Oncol. 2021 Oct 12. pii: S0090-8258(21)01386.
     PubMed    
     
     
     September 2021
157. VAN DER PLAS RCJ, Bos AME, Jurgenliemk-Schulz IM, Gerestein CG, et al
     Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
     Gynecol Oncol. 2021 Sep 25. pii: S0090-8258(21)01334.
     PubMed     Abstract available
     
     
     
158. LUHRS O, Ekdahl L, Geppert B, Lonnerfors C, et al
     Resection of the upper paracervical lymphovascular tissue should be an integral part of a pelvic sentinel lymph node algorithm in early stage cervical cancer.
     Gynecol Oncol. 2021 Sep 8. pii: S0090-8258(21)01328.
     PubMed     Abstract available
     
     
     
159. QIN J, Shahangian S, Saraiya M, Holt H, et al
     Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
     Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01321.
     PubMed     Abstract available
     
     
     
160. WANG Z, Guo E, Yang B, Xiao R, et al
     Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
     Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
     PubMed     Abstract available
     
     
     
161. WU S, Ding X, Kong Y, Acharya S, et al
     The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females.
     Gynecol Oncol. 2021 Sep 6. pii: S0090-8258(21)01314.
     PubMed     Abstract available
     
     
     
162. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
     From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?
     Gynecol Oncol. 2021 Sep 6. pii: S0090-8258(21)01324.
     PubMed     Abstract available
     
     
     
163. VENKAT P, Salani R
     Changing paradigms in intermediate-risk cervical cancer: Sedlis revisited.
     Gynecol Oncol. 2021;162:527-528.
     PubMed    
     
     
     
164. AO M, Zheng D, Wang J, Gu X, et al
     Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia.
     Gynecol Oncol. 2021;162:584-589.
     PubMed     Abstract available
     
     
     
165. GWACHAM NI, McKenzie ND, Fitzgerald ER, Ahmad S, et al
     Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.
     Gynecol Oncol. 2021;162:809-815.
     PubMed     Abstract available
     
     
     August 2021
166. MATZ M, Weir HK, Alkhalawi E, Coleman MP, et al
     Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3).
     Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01312.
     PubMed     Abstract available
     
     
     
167. O'MALLEY DM, Oaknin A, Monk BJ, Selle F, et al
     Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
     Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01316.
     PubMed     Abstract available
     
     
     
168. SALANI R, Liu JF
     The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
     Gynecol Oncol. 2021;162:245-248.
     PubMed    
     
     
     
169. KELTTO N, Leivonen A, Pankakoski M, Sarkeala T, et al
     Cervical testing beyond the screening target age - A register-based cohort study from Finland.
     Gynecol Oncol. 2021;162:315-321.
     PubMed     Abstract available
     
     
     July 2021
170. HRUDA M, Robova H, Rob L, Halaska MJ, et al
     Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Oncological outcomes.
     Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00593.
     PubMed     Abstract available
     
     
     
171. TIWARI R, Narayanan GS, Reddy VP, Vishwanathan B, et al
     Impact of nodal boost irradiation and MR-based brachytherapy on oncologic outcomes in node-positive cervical cancer.
     Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00585.
     PubMed     Abstract available
     
     
     
172. MURAKAMI N, Ando K, Murata M, Murata K, et al
     Why not de-intensification for uterine cervical cancer?
     Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00583.
     PubMed     Abstract available
     
     
     
173. HAESEN J, Salihi R, Van Gorp T, Van Nieuwenhuysen E, et al
     Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.
     Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00522.
     PubMed     Abstract available
     
     
     
174. CUZICK J, Du R, Adcock R, Kinney W, et al
     Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
     Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00525.
     PubMed     Abstract available
     
     
     
175. SPONHOLTZ SE, Mogensen O, Hildebrandt MG, Schledermann D, et al
     Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial).
     Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00512.
     PubMed     Abstract available
     
     
     
176. SALVADO A, Miralpeix E, Sole-Sedeno JM, Kanjou N, et al
     Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.
     Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00515.
     PubMed     Abstract available
     
     
     June 2021
177. LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
     Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
     Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00511.
     PubMed     Abstract available
     
     
     
178. CHATZISTAMATIOU K, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, et al
     Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
     Gynecol Oncol. 2021 Jun 28. pii: S0090-8258(21)00516.
     PubMed     Abstract available
     
     
     
179. VAN KEER S, Peeters E, Vanden Broeck D, De Sutter P, et al
     Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol.
     Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00490.
     PubMed     Abstract available
     
     
     
180. ZHANG G, Zhang Y, He F, Wu H, et al
     Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors.
     Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00492.
     PubMed     Abstract available
     
     
     
181. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
     Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
     Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
     PubMed     Abstract available
     
     
     
182. BENITO V, Lubrano A, Perez-Regadera JF, Torne A, et al
     Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
     Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00485.
     PubMed     Abstract available
     
     
     
183. RONSINI C, Anchora LP, Restaino S, Fedele C, et al
     The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients.
     Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00482.
     PubMed     Abstract available
     
     
     
184. MILLS JM, Morgan JR, Dhaliwal A, Perkins RB, et al
     Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
     Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00441.
     PubMed     Abstract available
     
     
     
185. PEI X, Xiang L, Chen W, Jiang W, et al
     The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
     Gynecol Oncol. 2021;161:779-786.
     PubMed     Abstract available
     
     
     May 2021
186. SERT BM, Kristensen GB, Kleppe A, Dorum A, et al
     Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.
     Gynecol Oncol. 2021 May 31. pii: S0090-8258(21)00434.
     PubMed     Abstract available
     
     
     
187. BRODEUR MN, Dejean R, Beauchemin MC, Samouelian V, et al
     Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
     Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00429.
     PubMed     Abstract available
     
     
     
188. SONG F, Belinson JL, Yan P, Huang X, et al
     Evaluation of p16(INK4a) immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China.
     Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00410.
     PubMed     Abstract available
     
     
     
189. ISHIKAWA M, Shibata T, Iwata T, Nishio S, et al
     A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Prim
     Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00403.
     PubMed     Abstract available
     
     
     
190. MATSUO K, Mandelbaum RS, Klar M, Ciesielski KM, et al
     Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States.
     Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00364.
     PubMed     Abstract available
     
     
     April 2021
191. DILLEY S, Huh W, Blechter B, Rositch AF, et al
     It's time to re-evaluate cervical Cancer screening after age 65.
     Gynecol Oncol. 2021 Apr 26. pii: S0090-8258(21)00347.
     PubMed     Abstract available
     
     
     
192. FANG C, Zhang P, Yu A, Yang Y, et al
     Different prognosis of stage IIIB cervical cancer patients with lower third of vaginal invasion and those without.
     Gynecol Oncol. 2021 Apr 12. pii: S0090-8258(21)00275.
     PubMed     Abstract available
     
     
     
193. DODD RH, Cvejic E, Bell K, Black K, et al
     Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study.
     Gynecol Oncol. 2021;161:179-187.
     PubMed     Abstract available
     
     
     March 2021
194. MATSUO K, Huang Y, Matsuzaki S, Ragab OM, et al
     Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic.
     Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00171.
     PubMed     Abstract available
     
     
     
195. CHANG CL, Ho SC, Su YF, Juan YC, et al
     DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
     Gynecol Oncol. 2021 Mar 20. pii: S0090-8258(21)00148.
     PubMed     Abstract available
     
     
     
196. ALHOLM Z, Monk BJ, Ting J, Pulgar S, et al
     Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
     Gynecol Oncol. 2021 Mar 16. pii: S0090-8258(21)00194.
     PubMed     Abstract available
     
     
     
197. KIM J, Cho Y, Kim N, Chung SY, et al
     Magnetic resonance imaging-based validation of the 2018 FIGO staging system in patients treated with definitive radiotherapy for locally advanced cervix cancer.
     Gynecol Oncol. 2021;160:735-741.
     PubMed     Abstract available
     
     
     February 2021
198. SKORSTENGAARD M, Frederiksen ME, Baillet MV, Beau AB, et al
     Cervical cancer survivors and health care use: A Danish population-based register study.
     Gynecol Oncol. 2021 Feb 19. pii: S0090-8258(21)00139.
     PubMed     Abstract available
     
     
     
199. VARELA CAGETTI L, Gonzague-Casabianca L, Zemmour C, Lambaudie E, et al
     The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer.
     Gynecol Oncol. 2021 Feb 6. pii: S0090-8258(21)00094.
     PubMed     Abstract available
     
     
     
200. BROOKS SE, Davis EC, Farley JH
     Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair.
     Gynecol Oncol. 2021;160:361-363.
     PubMed    
     
     
     January 2021
201. BOGANI G, Sopracordevole F, Di Donato V, Ciavattini A, et al
     High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes.
     Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00080.
     PubMed     Abstract available
     
     
     
202. CASTLE PE, Locke A, Tergas AI, Befano B, et al
     The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
     Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
     PubMed     Abstract available
     
     
     
203. KALJOUW S, Jansen EEL, Aitken CA, Harrijvan LM, et al
     Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
     Gynecol Oncol. 2021 Jan 12. pii: S0090-8258(20)34253.
     PubMed     Abstract available
     
     
     
204. KANAO H, Aoki Y, Omi M, Nomura H, et al
     Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: Technical feasibility and short-term oncologic outcome.
     Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34249.
     PubMed     Abstract available
     
     
     
205. ZAPARDIEL I, Kocian R, Kohler C, Klat J, et al
     Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX.
     Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34221.
     PubMed     Abstract available
     
     
     
206. BOGANI G, Raspagliesi F, di Donato V, Brusadelli C, et al
     Spotlight on the role of human papillomavirus vaccines.
     Gynecol Oncol. 2021;160:346-350.
     PubMed     Abstract available
     
     
     December 2020
207. DAHLMAN D, Li X, Magnusson H, Sundquist J, et al
     Cervical cancer among Swedish women with drug use disorders: A nationwide epidemiological study.
     Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34214.
     PubMed     Abstract available
     
     
     
208. JOU J, Coulter E, Roberts T, Binder P, et al
     Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation.
     Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34180.
     PubMed     Abstract available
     
     
     
209. FACHINI AMD, Zuliani AC, Sarian LO, Teixeira JC, et al
     Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.
     Gynecol Oncol. 2020 Dec 16. pii: S0090-8258(20)34157.
     PubMed     Abstract available
     
     
     
210. FORD S, Tarraf W, Williams KP, Roman LA, et al
     Differences in cervical cancer screening and follow-up for black and white women in the United States.
     Gynecol Oncol. 2020 Dec 12. pii: S0090-8258(20)34155.
     PubMed     Abstract available
     
     
     
211. PAREEK V, Barthwal M, Giridhar P, Patil PA, et al
     A phase III randomised trial of trans-abdominal ultrasound in improving application quality and dosimetry of intra-cavitary brachytherapy in locally advanced cervical cancer.
     Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34160.
     PubMed     Abstract available
     
     
     
212. SPINILLO A, Dominoni M, Boschi AC, Cesari S, et al
     The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia.
     Gynecol Oncol. 2020;159:630-635.
     PubMed     Abstract available
     
     
     
213. COHEN PA, Leung Y, Anderson L, van der Griend R, et al
     Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and
     Gynecol Oncol. 2020;159:623-629.
     PubMed     Abstract available
     
     
     
214. BOGANI G, DI Donato V, Sopracordevole F, Ciavattini A, et al
     Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.
     Gynecol Oncol. 2020;159:636-641.
     PubMed     Abstract available
     
     
     November 2020
215. STALEY SA, Tucker KR, Gehrig PA, Clark LH, et al
     Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery.
     Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34067.
     PubMed     Abstract available
     
     
     
216. JANSEN EEL, Ivanus U, Jerman T, de Koning HJ, et al
     The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
     Gynecol Oncol. 2020 Nov 13. pii: S0090-8258(20)34058.
     PubMed     Abstract available
     
     
     
217. DE LA MOTTE ROUGE T, Touboul C, Lhomel C, Roupret M, et al
     Factors associated with compliance to cervical cancer screening in France: The EDIFICE 6 survey.
     Gynecol Oncol. 2020 Nov 3. pii: S0090-8258(20)34054.
     PubMed     Abstract available
     
     
     
218. BREWSTER WR
     Insurance and adherence to guideline concordant cervical cancer therapy do not reduce mortality?
     Gynecol Oncol. 2020;159:297-298.
     PubMed    
     
     
     October 2020
219. HAN X, Liu S, Yang G, Hosseinifard H, et al
     Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
     Gynecol Oncol. 2020 Oct 19. pii: S0090-8258(20)34019.
     PubMed     Abstract available
     
     
     
220. HUNG P, Zahnd WE, Brandt HM, Adams SA, et al
     Cervical cancer treatment initiation and survival: The role of residential proximity to cancer care.
     Gynecol Oncol. 2020 Oct 17. pii: S0090-8258(20)34014.
     PubMed     Abstract available
     
     
     
221. KWON BS, Roh HJ, Lee S, Yang J, et al
     Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.
     Gynecol Oncol. 2020 Oct 8. pii: S0090-8258(20)33945.
     PubMed     Abstract available
     
     
     
222. BAO H, Bi H, Zhang X, Zhao Y, et al
     Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study.
     Gynecol Oncol. 2020;159:171-178.
     PubMed     Abstract available
     
     
     September 2020
223. CHINO J, Annunziata CM, Beriwal S, Bradfield L, et al
     The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.
     Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33908.
     PubMed    
     
     
     
224. LANDY R, Mathews C, Robertson M, Wiggins CL, et al
     A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.
     Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33850.
     PubMed     Abstract available
     
     
     
225. LI C, Li X, You J, Liang B, et al
     Impact of radiation source activity on short- and long-term outcomes of cervical carcinoma patients treated with high-dose-rate brachytherapy: A retrospective cohort study.
     Gynecol Oncol. 2020 Sep 12. pii: S0090-8258(20)33854.
     PubMed     Abstract available
     
     
     
226. CAO D, Shen K, Chen Y, Xu Y, et al
     Value of endocervical curettage in follow-up for patients with cervical intraepithelial neoplasia stage 2+ after loop electrosurgical excision.
     Gynecol Oncol. 2020;158:584-589.
     PubMed     Abstract available
     
     
     
227. FRUMOVITZ M, Westin SN, Salvo G, Zarifa A, et al
     Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
     Gynecol Oncol. 2020;158:570-575.
     PubMed     Abstract available
     
     
     July 2020
228. HUH WK, Brady WE, Fracasso PM, Dizon DS, et al
     Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
     Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32317.
     PubMed     Abstract available
     
     
     June 2020
229. BONAZZOLI E, Bellone S, Zammataro L, Gnutti B, et al
     Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
     Gynecol Oncol. 2020 Jun 26. pii: S0090-8258(20)32299.
     PubMed     Abstract available
     
     
     
230. VASSEUR D, Lopez J, Croce S, Tondeur G, et al
     Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression.
     Gynecol Oncol. 2020;157:775-782.
     PubMed     Abstract available
     
     
     April 2020
231. GULTEKIN M, Dundar S, Keskinkilic B, Turkyilmaz M, et al
     How to triage HPV positive cases: Results of four million females.
     Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31008.
     PubMed     Abstract available
     
     
     
232. REICH O, Regauer S, Kashofer K
     Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study.
     Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30985.
     PubMed     Abstract available
     
     
     February 2020
233. LI X, Xia L, Li J, Chen X, et al
     Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China.
     Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30152.
     PubMed     Abstract available
     
     
     
234. CHARO LM, Vaida F, Eskander RN, Binder P, et al
     Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial.
     Gynecol Oncol. 2020 Feb 17. pii: S0090-8258(20)30154.
     PubMed     Abstract available
     
     
     January 2020
235. MATERN T, Kang E, Lim PC
     Factors in the feasibility and safety of outpatient robotic-assisted hysterectomy for endometrial or cervical carcinoma.
     Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30081.
     PubMed     Abstract available
     
     
     
236. TRIMBLE CL, Levinson K, Maldonado L, Donovan MJ, et al
     A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3).
     Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31865.
     PubMed     Abstract available
     
     
     
237. LI T, Wu Z, Jiang M, Zhao Y, et al
     Clinical performance of Onclarity HPV assay and Cobas HPV test in detection of cervical precancer and cancer in Chinese women.
     Gynecol Oncol. 2020 Jan 18. pii: S0090-8258(20)30022.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.